Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Researchers find how HRT and the Pill can lead to breast cancer and suggest possible treatment

Medical scientists have uncovered how hormone replacement therapy and contraceptive pills can lead to breast cancer, according to research published online by Nature today (Wednesday 29 September, 2010). The findings raise the hope that hormone induced breast cancer may be prevented in future using a new treatment for the bone-loss disease osteoporosis.

Breast cancer is one of the most common cancers, affecting up to one in eight women during their lives in Europe, the UK and USA. Large population studies such as the Women’s Health Initiative and the Million Women Study have shown that synthetic sex hormones called progestins used in hormone replacement therapy, HRT, and in contraceptives can increase the risk of breast cancers.

Now medical researchers at the Institute of Molecular Biotechnology of the Austrian Academy of Sciences in Vienna have identified a key mechanism which allows these synthetic sex hormones to directly affect mammary cells.

The research builds on previous work by Prof Josef Penninger, the IMBA director, who found the first genetic evidence that a protein called RANKL is the master regulator of healthy bones. In a complex system that regulates bone mass, RANKL activates the cells that break down bone material when it needs to be replaced. When the system goes wrong and we make too much of the protein it triggers bone loss, leading to osteoporosis in millions of patients around the world every year. Finding exactly the same molecule in breast tissues led the scientists to the new link between sex hormones and breast cancer.

In a scientific article published on Nature’s website today, the research team show that a synthetic female sex hormone used in HRT and contraceptive pills can trigger RANKL in breast cells of mice. As a consequence, these mammary cells start to divide and multiply and fail to die when they should. Moreover, stem cells in the breast become able to renew themselves, ultimately resulting in breast cancer.

In a different set of mouse treatment tests, reported in a second Nature article also published today, researchers at Amgen have found that pharmacologic blocking of the RANKL system significantly delays mammary tumor formation leading to significantly fewer breast cancers in mice. In another mouse model, RANKL inhibition not only decreased breast tumor formation but also reduced lung metastasis.

“Ten years ago we formulated the hypothesis that RANKL might be involved in breast cancer and it took us a long time to develop systems to prove this idea”, says Prof Josef Penninger. ” I have to admit it completely surprised me just how massive the effects of the system were. Millions of women take progesterone derivatives in contraceptives and for hormonal replacement therapy. Since our results show that the RANKL system is an important molecular link between a synthetic sex hormone and breast tumors, one day women may be able to reduce their risk by taking blocking medicines in advance to prevent breast cancer”.

A monoclonal antibody, denosumab, that blocks RANKL has been recently approved in the US and the EU for the treatment of osteoporosis, and is currently under review for the treatment of bone metastases in patients with advanced cancer. “Further studies will be needed to prove the principle of our findings”, says Dr Daniel Schramek, who carried out the studies with Prof Josef Penninger at the Institute of Molecular Biotechnology in Vienna. “But we hope that medical trials using denosumab can be started in the near future to test whether the mouse studies can be directly translated to human breast cancer.”

This work was an international collaboration between lead researchers at IMBA and scientists at the Medical University of Vienna; the Garvan Institute of Medical Research, Sydney, Australia; the Ontario Cancer Institute, University of Toronto, Toronto, Canada; Harvard School of Public Health, Harvard Medical School and the Ragon Institute of MGH/MIT and Harvard, Boston, USA; the Institute for Genetics, Centre for Molecular Medicine (CMMC), and Cologne Excellence Cluster (CECAD), University of Cologne, Germany; University College London, UK; and the University of Erlangen-Nuremberg, Germany.

Notes to News Editors:

(1) A high quality copyright-free colour image of the human body showing breast cancer cell activation is available for free reproduction (with acknowledgement to IMBA) on request, or download directly from the website http:///

(2) RANK = Receptor Activator of Nuclear Factor ê B, this receptor is a membrane protein

RANKL = Receptor Activator of Nuclear Factor ê B Ligand, this is a chemical messenger which binds to RANK and activates it.

(3) Nature Advance Online Publication, Sept. 29, 2010, DOI 10.1038/nature09387. Title: Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer (Schramek et al.)

See also DOI 10.1038/nature09495. Title: RANK Ligand is a Critical Mediator of Hormone and Carcinogen-Induced Mammary Epithelial Proliferation and Progression to Adenocarcinoma (Gonzalez-Suarez et al.)

(4) About IMBA
The IMBA – Institute for Molecular Biotechnology of the Austrian Academy of Sciences – opened in 2003. It combines fundamental and applied research in the field of biomedicine. Interdisciplinary research groups address functional genetic questions, particularly those related to the origin of disease. The ultimate goal is to implement acquired knowledge into the development of innovative applications for prevention, diagnosis and treatment of disease.
IMP - IMBA Research Center
A cooperation contract links the Institute of Molecular Biotechnology of the Austrian Academy of Sciences (IMBA) to the Research Institute of Molecular Pathology (IMP), which has operated since 1988 and is supported by Boehringer Ingelheim. Under the name of the “IMP – IMBA Research Center”, both institutes have access to a combined infrastructure in scientific and administrative areas. Together, the two institutes employ around 400 staff from 30 nations and are members of the Campus Vienna Biocenter.

For further information contact:

Dr Heidemarie Hurtl, Communications, Institute of Molecular Biotechnology, Vienna
Address: Dr. Bohr Gasse 7, A-1030 Vienna, Austria
Tel. +43 1 79730/3625 Mobile: +43 664 8247910
Fax: +43 1 7987153
Professor Josef Penninger, Director, Institute of Molecular Biotechnology, Vienna
Tel. +43 1 79730/4700
Dr Daniel Schramek, Institute of Molecular Biotechnology, Vienna
Tel. +43 1 79730/4731

Dr. Heidemarie Hurtl | idw
Further information:

More articles from Life Sciences:

nachricht Novel mechanisms of action discovered for the skin cancer medication Imiquimod
21.10.2016 | Technische Universität München

nachricht Second research flight into zero gravity
21.10.2016 | Universität Zürich

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New 3-D wiring technique brings scalable quantum computers closer to reality

Researchers from the Institute for Quantum Computing (IQC) at the University of Waterloo led the development of a new extensible wiring technique capable of controlling superconducting quantum bits, representing a significant step towards to the realization of a scalable quantum computer.

"The quantum socket is a wiring method that uses three-dimensional wires based on spring-loaded pins to address individual qubits," said Jeremy Béjanin, a PhD...

Im Focus: Scientists develop a semiconductor nanocomposite material that moves in response to light

In a paper in Scientific Reports, a research team at Worcester Polytechnic Institute describes a novel light-activated phenomenon that could become the basis for applications as diverse as microscopic robotic grippers and more efficient solar cells.

A research team at Worcester Polytechnic Institute (WPI) has developed a revolutionary, light-activated semiconductor nanocomposite material that can be used...

Im Focus: Diamonds aren't forever: Sandia, Harvard team create first quantum computer bridge

By forcefully embedding two silicon atoms in a diamond matrix, Sandia researchers have demonstrated for the first time on a single chip all the components needed to create a quantum bridge to link quantum computers together.

"People have already built small quantum computers," says Sandia researcher Ryan Camacho. "Maybe the first useful one won't be a single giant quantum computer...

Im Focus: New Products - Highlights of COMPAMED 2016

COMPAMED has become the leading international marketplace for suppliers of medical manufacturing. The trade fair, which takes place every November and is co-located to MEDICA in Dusseldorf, has been steadily growing over the past years and shows that medical technology remains a rapidly growing market.

In 2016, the joint pavilion by the IVAM Microtechnology Network, the Product Market “High-tech for Medical Devices”, will be located in Hall 8a again and will...

Im Focus: Ultra-thin ferroelectric material for next-generation electronics

'Ferroelectric' materials can switch between different states of electrical polarization in response to an external electric field. This flexibility means they show promise for many applications, for example in electronic devices and computer memory. Current ferroelectric materials are highly valued for their thermal and chemical stability and rapid electro-mechanical responses, but creating a material that is scalable down to the tiny sizes needed for technologies like silicon-based semiconductors (Si-based CMOS) has proven challenging.

Now, Hiroshi Funakubo and co-workers at the Tokyo Institute of Technology, in collaboration with researchers across Japan, have conducted experiments to...

All Focus news of the innovation-report >>>



Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

Agricultural Trade Developments and Potentials in Central Asia and the South Caucasus

14.10.2016 | Event News

World Health Summit – Day Three: A Call to Action

12.10.2016 | Event News

Latest News

Resolving the mystery of preeclampsia

21.10.2016 | Health and Medicine

Stanford researchers create new special-purpose computer that may someday save us billions

21.10.2016 | Information Technology

From ancient fossils to future cars

21.10.2016 | Materials Sciences

More VideoLinks >>>